唐克，博士，副研究员。2007年毕业于中国药科大学药学专业，获学士学位；2014年毕业于北京协和医学院药物研究所药理学专业，获博士学位。主持国家自然科学基金等3项基金，参与十一五、十二五、十三五“重大新药创制”国家科技重大专项及省部级课题4项。研究成果获授权专利11项，发表多篇研究性论文。

1、治疗特应性皮炎的新药发现及机制研究。
2、抗病毒药效学评价（流感病毒、HIV、HCV、呼吸道合胞病毒等）。

近5年代表性成果：
1. Chen S#, Xin Y#, Tang K, Wu Y, Guo Y*. Nardosinone and aurantio-obtusin, two medicine food homology natural compounds, are anti-influenza agents as indicated by transcriptome signature reversion. Phytomedicine. 2023,108:154515.
2. Tang K#, Wu Y#, Chen S, Xin Y, Guo Y*. Discovery of the anti-influenza A virus activity of SB216763 and cyclosporine A by mining infected cells and compound cellular signatures. Chin Chem Lett. 2022,33(5):2541-2544.
3. Xin Y#, Chen S#, Tang K, Wu Y, Guo Y*. Identification of nifurtimox and chrysin as anti-influenza virus agents by clinical transcriptome signature reversion. Int. J. Mol. Sci. 2022, 23(4):2372.
4. Tang K#, Zhang X#, Guo Y*. Identification of the dietary supplement capsaicin as an inhibitor of Lassa virus entry. Acta Pharm Sin B, 2020,10(5):789-798.
5. Zhang X, Tang K, Guo Y*. The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein. Antiviral Res. 2020,174:104701.
6. Chen Q, Tang K, Guo Y*. Discovery of sclareol and sclareolide as filovirus entry inhibitors. J Asian Nat Prod Res. 2020,22(5):464-473.
7. Zhang X#, Yan F#, Tang K, Chen Q, Guo J, Zhu W, He S, Banadyga L, Qiu X*, Guo Y*. Identification of a clinical compound losmapimod that blocks Lassa virus entry. Antiviral Res. 2019, 167: 68-77.

授权专利11项（授权公告号：CN 107149602B、CN 107149603 B、CN 107176921 B、CN 107151231 B、CN 107174581 B、CN107151223B等）